Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0XQCQY
ADC Name	CN105828840B ADC-134
Synonyms	CN105828840B ADC-134 Click to Show/Hide
Organization	Genentech Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	1.8
	3D MOL	2D MOL
Antibody Name	CN105828840B_ADC-134 antibody
Antigen Name	Sodium-dependent phosphate transport protein 2B (SLC34A2)		Antigen Info
Payload Name	Undisclosed
Linker Name	CN105828840B_ADC-134 linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≍ 57.1	%	CVCL_1304	Ovarian endometrioid adenocarcinoma
Tumor Growth Inhibition value (TGI)	≍ 85.7	%	CVCL_1304	Ovarian endometrioid adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 57.10% (Day 21)	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 1 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≍ 85.70% (Day 21)	Positive SLC34A2 expression (SLC34A2+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	IGROV-1 CDX model
In Vitro Model	Ovarian endometrioid adenocarcinoma	IGROV-1 cells		CVCL_1304

References

Ref 1	1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment.